English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 903923      Online Users : 707
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12018


    Title: Linker optimization and therapeutic evaluation of phosphatidylserine-targeting zinc dipicolylamine-based drug conjugates
    Authors: Liu, YW;Chen, YY;Hsu, CY;Chiu, TY;Liu, KL;Lo, CF;Fang, MY;Huang, YC;Yeh, TK;Pak, KY;Gray, BD;Hsu, TA;Huang, KH;Shih, C;Shia, KS;Chen, CT;Tsou, LK
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: We report that compound 13, a novel phosphatidylserine-targeting zinc(II) dipicolylamine drug conjugate, readily triggers a positive feedback therapeutic loop through the in situ generation of phosphatidylserine in the tumor microenvironment. Linker modifications, pharmacokinetics profiling, in vivo antitumor studies, and micro-Western array of treated-tumor tissues were employed to show that this class of conjugates induced regeneration of apoptotic signals, which facilitated subsequent recruitment of the circulating conjugates through the zinc(II) dipicolylamine-phosphatidylserine association and resulted in compounding antitumor efficacy. Compared to the marketed compound 17, compound 13 not only induced regressions in colorectal and pancreatic tumor models, it also exhibited at least 5-fold enhancement in antitumor efficacy with only 40% of the drug employed during treatment, culminating in a >12.5-fold increase in therapeutic potential. Our study discloses a chemically distinct apoptosis-targeting theranostic, with built-in complementary functional moieties between the targeting module and the drug mechanism to expand the arsenal of antitumor therapy.
    Date: 2019-07-11
    Relation: Journal of Medicinal Chemistry. 2019 Jul 11;62(13):6047-6062.
    Link to: http://dx.doi.org/10.1021/acs.jmedchem.9b00173
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0022-2623&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000475543300007
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85068148444
    Appears in Collections:[鄒倫] 期刊論文
    [陳炯東] 期刊論文
    [夏克山] 期刊論文
    [石全(2014-2017)] 期刊論文
    [徐祖安] 期刊論文
    [葉燈光] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB31181158.pdf5377KbAdobe PDF333View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback